Quotient Limited Announces Appointment of Christopher Lindop as Chief Financial Officer
February 09 2017 - 4:05PM
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics
company, today announced the appointment of Christopher Lindop as
Chief Financial Officer. Mr. Lindop will commence his new
role on February 15, 2017.
Mr. Lindop joins Quotient with more than a
decade of financial leadership experience within high-growth
diagnostic and blood management companies. Most recently, Mr.
Lindop served as Chief Financial Officer and Executive Vice
President of Business Development at Haemonetics Corporation
(NYSE:HAE), a publicly traded hematology management company, where
he oversaw financial organization, strategic planning, business
development and investor relations during a period of rapid growth.
Prior to joining Haemonetics in January 2007, Mr. Lindop served as
Chief Financial Officer at Inverness Medical Innovations, now Alere
Inc., a publicly traded diagnostics company, where he developed a
financial infrastructure to support rapid expansion and led
multiple financings. Prior to joining Inverness, Mr. Lindop was a
Partner at both Arthur Andersen and Ernst & Young. Mr. Lindop
currently serves on the Board of Directors at Parexel International
(NASDAQ:PRXL), a publicly traded biopharmaceutical consulting
company. Mr. Lindop holds a B.A. in Business from the University of
Strathclyde (Scotland).
“We are excited to have Chris join us during
such a pivotal period as we work towards the commercial launch of
MosaiQTM,” said Paul Cowan, Quotient’s Chairman and Chief Executive
Officer. “His vast experience in helping to lead diagnostic and
blood management companies through periods of high growth will be
invaluable.”
About Quotient Limited
Quotient is a commercial-stage diagnostics
company committed to reducing healthcare costs and improving
patient care through the provision of innovative tests within
established markets. With an initial focus on blood grouping and
serological disease screening, Quotient is developing its
proprietary MosaiQ™ technology platform to address the $3.4 billion
global transfusion diagnostics market. The Company's operations are
based in Switzerland, Scotland and the US.
The Quotient logo and MosaiQ™ are registered
trademarks or trademarks of Quotient Limited and its subsidiaries
in various jurisdictions.
CONTACT: Paul Cowan, Chairman & Chief Executive Officer — CEO@quotientbd.com; +1 267 756 0842
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Apr 2023 to Apr 2024